FDA Reviewing Biomoda Submission for Cancer Screening Study

2008-08-04 12:57:00

FDA Reviewing Biomoda Submission for Cancer Screening Study

    ALBUQUERQUE, N.M., Aug. 4 /EMWNews/ -- Biomoda, Inc. (OTC

Bulletin Board: BMOD) (http://www.biomoda.com), a development stage medical

diagnostics company, submitted to the FDA a pre-IDE (Investigational Device

Exemption) protocol for a clinical study using Biomoda's proprietary assay

for detection of early lung cancer in veterans. The New Mexico state

legislature allocated more than $1.6 million over two years towards the

study that will screen more than 2000 veterans.



    "This is an essential step in study development," said John Cousins,

President of Biomoda. "Approval by the FDA of the study design this year

allows us to move forward quickly to prove the efficacy of the assay.

Approval by the Agency of the results of this study that we expect early

next year will provide us the ability to market our assay commercially."



    Biomoda's patented technology is designed for early lung cancer

screening of large populations at a reasonable cost. The non-invasive test,

originally developed at Los Alamos National Laboratory, allows clinicians

to identify cancerous or aberrant cells extracted from samples of lung

sputum; cancerous cells in the sputum exposed to the assay glow red under

fluorescent light and can be detected under a microscope.



    Earlier this year, Biomoda and the New Mexico Institute of Mining and

Technology announced their partnership with the New Mexico Department of

Veterans Services to conduct a two-phase study of the state's veterans. The

initial phase will screen 225 veterans; a second phase will test more than

2000 veterans for lung cancer using Biomoda's non-invasive patented assay.



    Lung cancer claims more lives than any other cancer. The expected

five-year survival rate for all patients diagnosed with lung cancer is 15%;

the five-year survival rate for cases detected when the disease is still

localized is 50 percent. Presently, only 16% of lung cancer cases are

diagnosed at this early stage.




For more information contact: John Cousins 505-821-0875 investor@biomoda.com Forward Looking Statement All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of BIOMODA's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. BIOMODA, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in BIOMODA's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website 
TheNFG.com now offers Organic Lead Generation & Traffic Solutions





























Leave a Reply

Your email address will not be published. Required fields are marked *

*